Results 61 to 70 of about 205,639 (219)
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Molecular Oncology, EarlyView.Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
Molecular Oncology, EarlyView.We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
Molecular Oncology, EarlyView.Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez +5 more
wiley +1 more source
Molecular Oncology, EarlyView.The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Drug Design, Development and TherapyQianlei Ye,1,2,* Wei Xing,2,* Xuefeng Hu,2 Wenjuan Liu,2 Jigang Wu,2 Hailan Huang,2 Ying Xiao,2 Yanjun Hong1 1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, People’s Republic of China; 2Shenzhen Salubris ...
Ye Q +7 more
doaj
Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies
ADMET and DMPKBackground and purpose: The delivery of therapeutics to the central nervous system (CNS) remains a major challenge due to the restrictive nature of the blood-brain barrier (BBB), a key evolutionary feature that preserves brain homeostasis.
Ronny Vargas +8 more
doaj +1 more source
Molecular Oncology, EarlyView.LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Multitask CapsNet: An Imbalanced Data Deep Learning Method for Predicting Toxicants
ACS Omega, 2021 Yiwei Wang +6 more
doaj +1 more source
Frontiers in Cardiovascular MedicineBackgroundOlanzapine is an atypical antipsychotic used to treat schizophrenia and manic episodes. Its potential thromboembolic risk has been reported, but the evidence remains controversial.
XueSong Zhang +13 more
doaj +1 more source